GB202115077D0 - Assay - Google Patents

Assay

Info

Publication number
GB202115077D0
GB202115077D0 GBGB2115077.6A GB202115077A GB202115077D0 GB 202115077 D0 GB202115077 D0 GB 202115077D0 GB 202115077 A GB202115077 A GB 202115077A GB 202115077 D0 GB202115077 D0 GB 202115077D0
Authority
GB
United Kingdom
Prior art keywords
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2115077.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GBGB2115077.6A priority Critical patent/GB202115077D0/en
Publication of GB202115077D0 publication Critical patent/GB202115077D0/en
Priority to PCT/EP2022/079144 priority patent/WO2023067031A2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
GBGB2115077.6A 2021-10-21 2021-10-21 Assay Ceased GB202115077D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2115077.6A GB202115077D0 (en) 2021-10-21 2021-10-21 Assay
PCT/EP2022/079144 WO2023067031A2 (en) 2021-10-21 2022-10-19 Assay

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2115077.6A GB202115077D0 (en) 2021-10-21 2021-10-21 Assay

Publications (1)

Publication Number Publication Date
GB202115077D0 true GB202115077D0 (en) 2021-12-08

Family

ID=78805967

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2115077.6A Ceased GB202115077D0 (en) 2021-10-21 2021-10-21 Assay

Country Status (2)

Country Link
GB (1) GB202115077D0 (en)
WO (1) WO2023067031A2 (en)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (en) 1978-11-11 1980-05-22 Behringwerke Ag METHOD FOR PRODUCING MEMBRANE PROTEINS FROM NEISSERIA MENINGITIDIS AND VACCINE CONTAINING THEM
US5698438A (en) 1994-10-18 1997-12-16 Oregon Health Sciences University Bacterial hemoglobin receptor gene
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
EP1645631B1 (en) 1998-05-01 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Neisseria antigens and compositions
CA2390344C (en) 1999-11-29 2014-08-26 Chiron Spa 85kda neisserial antigen
BRPI0112928B1 (en) 2000-07-27 2017-08-29 Children's Hospital & Research Center At Oakland A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US20100035234A1 (en) * 2008-05-19 2010-02-11 Novartis Ag Vaccine assays
JP2012512240A (en) 2008-12-17 2012-05-31 ノバルティス アーゲー Meningococcal vaccine containing hemoglobin receptor
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
WO2012031271A1 (en) * 2010-09-04 2012-03-08 Novartis Ag Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
EP2823312B1 (en) * 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

Also Published As

Publication number Publication date
WO2023067031A2 (en) 2023-04-27
WO2023067031A3 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
GB201807409D0 (en) Assay
GB201819187D0 (en) Assay
GB2600719B (en) Fluorescence assay
GB202008994D0 (en) Assay method
GB202011617D0 (en) Assay
GB202016699D0 (en) Antibody assay
GB201905090D0 (en) Assay device
GB201903009D0 (en) Assay device
EP4060017A4 (en) Assay chip
IL307174A (en) Assay
GB202119033D0 (en) Assay
GB202117513D0 (en) Assay
GB202115072D0 (en) Assay
GB202115077D0 (en) Assay
GB202112296D0 (en) Assay
GB202109886D0 (en) Assay
GB202108853D0 (en) Assay
GB202105117D0 (en) Assay
GB202015211D0 (en) Assay
GB202015122D0 (en) Assay
GB202014570D0 (en) Complementome assay
GB202006987D0 (en) Improved assay
GB202001496D0 (en) Improved assay
GB202001203D0 (en) Improved assay
GB202307576D0 (en) C3a1-hne assay

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)